Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72218/1/j.1572-0241.2008.02200.x.pd

Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures

The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment

Prospective study of biliary strictures to determine the predictors of malignancy

ORIGINAL ARTICLE BACKGROUND: There have been few prospective studies regarding the investigation of biliary strictures, principally because of rapid technological change. The present study was designed to determine the sensitivity of various imaging studies for the detection of biliary strictures. Serum biochemistry and imaging studies were evaluated for their role in distinguishing benign from malignant strictures. METHODS: Thirty-one patients with suspected noncalculus biliary obstruction were enrolled consecutively in the study. A complete biochemical profile, ultrasound, Disida scan and cholangiogram (endoscopic retrograde cholangiopancreatography [ERCP] or percutaneous cholangiogram) were obtained at study entry. Stricture etiology was determined based on cytology, biopsy and/or clinical follow-up at one year. RESULTS: Twenty-nine of 31 patients had biliary strictures, of which 15 were malignant. The mean age of the malignant cohort was 73.9 years versus 53.9 years in the benign cohort (P<0.001). Statistically significant differences between the malignant and benign groups, respectively, were as follows: alanine transaminase 235.2 versus 66.9 U/L (P=0.004), aspartate transaminase 189.8 versus 84.5 U/L (P=0.011), alkaline phosphatase 840.2 versus 361.1 U/L (P=0.002), bilirubin 317.8 versus 22.1 µmol/L (P<0.001) and bile acids 242.5 versus 73.2 µmol/L (P=0.001). Threshold analysis using receiver operative characteristic (ROC) curves demonstrated that a bilirubin level of 75 µmol/L was most predictive of malignant strictures. Intrahepatic duct dilation was present in 93% of malignant strictures versus 36% of benign strictures (P=0.002). Common hepatic duct dilation was less discriminatory (malignant 13.5 versus benign 9.6 mm; P=0.11). Ultrasound was highly sensitive (93%) in the detection of the primary tumour in the bile duct or pancreas, or in the visualization of nodal or liver metastases. In benign disease, ultrasound failed to detect evidence of intrahepatic or extrahepatic biliary dilation in most cases. Disida scans were not able to distinguish between malignant or benign strictures and could not accurately localize the level of obstruction. The sensitivity of Disida scan for the diagnosis of obstruction was 50%. Cholangiographic characterization of strictures revealed an equal distribution of smooth (eight of 13) and irregular (five of 13) strictures in the malignant group. Ten of 13 benign strictures were characterized as smooth. Malignant strictures were significantly longer than benign ones -30.3 versus 9.2 mm (P=0.001). Threshold analysis using ROC curves showed that strictures greater than or equal to 14 mm were predictive of malignancy (sensitivity 78%, specificity 75%, log odds ratio 11.23). CONCLUSIONS: A serum bilirubin level of 75 µmol/L or higher, or a stricture length of greater than 14 mm was highly predictive of malignancy in patients with a biliary stricture. Ultrasound was useful in predicting malignant strictures by detecting either intrahepatic duct dilation or by visualizing the tumour (primary or metastases). Strictures with a 'benign' cholangiographic appearance are frequently malignant. Disida scan did not add additional information. ERCP is necessary to diagnose benign strictures, which tend to be less extensive at presentation. B iliary strictures are a challenging problem for the clinician. By the time that patients with biliary strictures are referred to a specialist, the diagnosis is usually already known or strongly suspected because clinical evaluation and noninvasive investigations alone have a high specificity and sensitivity (1-4). The job of the medical or surgical specialist is not only to confirm the diagnosis of biliary stricture but also, importantly, to define the etiology and the exact anatomic location, which is vital to therapeutic planning. The differentiation between benign and malignant strictures can be difficult but is of obvious importance in regard to prognosis and optimal therapy. Numerous imaging modalities are available for the investigation of biliary strictures, including abdominal ultrasound, computed tomographic (CT) scanning, nuclear imaging, percutaneous transhepatic cholangiography (PTC), endoscopic retrograde cholangiopancreatography (ERCP) and most recently magnetic resonance cholangiopancreatography (MRCP). Comparative and descriptive studies in this area are lacking, primarily because rapid technological improvements and developments outdate them. We, therefore, embarked on a prospective descriptive trial with the following aims: · Determine the predictive value of liver enzymes, serum bilirubin, serum bile acids, ultrasound and diethyl-iminodiacetic acid (Disida) nuclear imaging for the presence of malignant biliary strictures. · Measure the ability of ultrasound and nuclear imaging to localize the level of obstruction using direct cholangiography as the gold standard. · Determine the sensitivity of abdominal ultrasound and Disida nuclear scanning for the detection of biliary strictures. · Investigate the utility of various cholangiographic features to distinguish malignant from benign strictures. PATIENTS AND METHODS Patients: All patients with biliary strictures referred to the Division of Gastroenterology at the University of Alberta Hospitals for investigation between January 1, 1995 and December 31, 1995 were prospectively entered into the trial. The inclusion criteria were age 16 years or older and noncalculus biliary obstruction. Patients were excluded if subsequent evaluation did not show a stricture. Ethics committee approval was obtained. sente dans 93 % des sténoses malignes par rapport à 36 % des sténoses béni-gnes (P = 0,002). Une dilatation du canal hépatique commun était moins discriminatoire (13,5 mm en cas de malignité par rapport à 9,6 mm en cas de bénignité, P = 0,11). L'échographie était hautement sensible (93 %) pour déceler la tumeur primaire dans le canal biliaire ou le pancréas, ou pour visualiser les nodules ou les métastases hépatiques. Dans le cas d'une maladie bénigne, l'échogra-phie n'a pas réussi à déceler la présence d'une dilatation biliaire intra-hépa-tique ou extra-hépatique dans la plupart des cas. Les scintigraphies au disida n'ont pas pu différencier les sténoses malignes des sténoses bénignes ou localiser précisément le niveau de l'obstruction. La sensibilité des scintigraphies au disida pour établir un diagnostic d'obstruction était de 50 %. La caractérisation cholangiographique des sténoses a révélé une distribution égale de sténoses lisses (huit sur 13) et irrégulières (cinq sur 13) dans le groupe des sténoses malignes. Dix des 13 sténoses bénignes ont été qualifiées de lisses. Les sténoses malignes étaient nettement plus longues que les sténoses bénignes, soit 30,3 mm par rapport à 9,2 mm (P=0,001). L'analyse des seuils au moyen des courbes ROC a révélé que des sténoses supérieures ou égales à 14 mm étaient un prédicteur de malignité (sensibilité de 78 %, spécificité de 75 %, risque relatif logarithmique de 11,23). CONCLUSIONS : Un niveau de bilirubine sérique de 75 µmol/L ou une longueur de sténose de 14 mm étaient fortement prédictifs de malignité chez les patients atteints d'une sténose biliaire. L'échographie était utile pour prédire les sténoses malignes en décelant soit une dilatation du canal intra-hépatique ou en visualisant la tumeur (primaire ou métastases). Les sténoses d'apparence « bénigne » à la cholangiographie s'avèrent souvent malignes. La scintigraphie au disida n'apportait pas d'informations supplé-mentaires. Une CPRE est nécessaire pour diagnostiquer des sténoses bénignes, qui ont tendance à être moins étendues à l'examen. · Abdominal ultrasound examination with particular attention to intrahepatic biliary dilation, extrahepatic duct calibre, presence or absence of gallbladder and other relevant pathology such as tumour mass or ductal stones. · Disida scan. Patients were examined after a 4 h fast. Opiates were withheld for the proceeding 24 h. In addition to the standard scan, data were collected for deconvolutional analysis to determine hepatic extraction fraction and time activity curve so that the half-life of biliary excretion and time to peak activity could be analyzed. · Cholangiography. ERCP was attempted first in all patients with failures proceeding to PTC. Cefazoline 1 g was administered intravenously 30 to 60 mins before cholangiography. The biliary system was filled as completely as possible using 50% Conray 60 (Mallenchrodt, St Louis, Missouri) contrast injected under low pressure. The information obtained from each cholangiogram included site of stricture, multiplicity, character (smoothly tapered versus irregular or shouldered), stricture(s) length, minimal stricture width, maximal proximal biliary dilation and other information (ampullary mass, primary sclerosing cholangitis, cancer of the pancreas). All data were to be collected within five working days so that the different imaging modalities tested would be comparable. All imaging studies were interpreted by radiologists blinded to the results of the patients' other diagnostic studies. The ERCP data were obtained last so that a biliary stent could be inserted if indicated. The cholangiographic measurements were confirmed by two independent observers. Stricture etiology was defined by cytology or biopsy histology or by clinical outcome after one year. Statistical analysis: Statistical analysis was performed using SPSS. Between-groups differences in mean values of continuous variables were tested by independent samples t tests or by nonparametric Mann-Whitney Rank Sum tests when the distributions were not normal. The differences in frequencies of categorical variables were tested by c 2 test with Yates' correction for continuity or by Fisher's exact test when the expected number of observations per cell was less than five. Associations between continuous variables were assessed by Pearson correlation coefficient. Logistic regression analysis was used to analyze the association of dichotomous outcome variable (malignant versus benign) with continuous and categorical predictor variables. The statistical inferences were based on the level of significance P<0.05. Receiver operating characteristic (ROC) curves were constructed for the biochemical variables. To determine optimal threshold levels for each diagnostic parameter, ROC plots were constructed using the observed true and false positive rates at each potential threshold level. A best fit ROC curve was constructed according to methods published elsewhere (5,6). The threshold value providing the best compromise between true and false positive rates was estimated from the ROC plot. Likelihood ratios were calculated from the fitted ROC curve. RESULTS Thirty-one patients were enrolled in the study. Two patients were excluded -one because he did not have a stricture and one whose suspected stricture was unevaluable because of previous biliary bypass and contraindication for PTC as a result of coagulopathy. Of the remaining 29 patients, 15 were diagnosed with malignant strictures and 14 with benign strictures. Two patients had primary sclerosing cholangitis, both of whom had multiple strictures. Patient demographics and underlying diagnosis are shown i

BHPR research: qualitative1. Complex reasoning determines patients' perception of outcome following foot surgery in rheumatoid arhtritis

Background: Foot surgery is common in patients with RA but research into surgical outcomes is limited and conceptually flawed as current outcome measures lack face validity: to date no one has asked patients what is important to them. This study aimed to determine which factors are important to patients when evaluating the success of foot surgery in RA Methods: Semi structured interviews of RA patients who had undergone foot surgery were conducted and transcribed verbatim. Thematic analysis of interviews was conducted to explore issues that were important to patients. Results: 11 RA patients (9 ♂, mean age 59, dis dur = 22yrs, mean of 3 yrs post op) with mixed experiences of foot surgery were interviewed. Patients interpreted outcome in respect to a multitude of factors, frequently positive change in one aspect contrasted with negative opinions about another. Overall, four major themes emerged. Function: Functional ability & participation in valued activities were very important to patients. Walking ability was a key concern but patients interpreted levels of activity in light of other aspects of their disease, reflecting on change in functional ability more than overall level. Positive feelings of improved mobility were often moderated by negative self perception ("I mean, I still walk like a waddling duck”). Appearance: Appearance was important to almost all patients but perhaps the most complex theme of all. Physical appearance, foot shape, and footwear were closely interlinked, yet patients saw these as distinct separate concepts. Patients need to legitimize these feelings was clear and they frequently entered into a defensive repertoire ("it's not cosmetic surgery; it's something that's more important than that, you know?”). Clinician opinion: Surgeons' post operative evaluation of the procedure was very influential. The impact of this appraisal continued to affect patients' lasting impression irrespective of how the outcome compared to their initial goals ("when he'd done it ... he said that hasn't worked as good as he'd wanted to ... but the pain has gone”). Pain: Whilst pain was important to almost all patients, it appeared to be less important than the other themes. Pain was predominately raised when it influenced other themes, such as function; many still felt the need to legitimize their foot pain in order for health professionals to take it seriously ("in the end I went to my GP because it had happened a few times and I went to an orthopaedic surgeon who was quite dismissive of it, it was like what are you complaining about”). Conclusions: Patients interpret the outcome of foot surgery using a multitude of interrelated factors, particularly functional ability, appearance and surgeons' appraisal of the procedure. While pain was often noted, this appeared less important than other factors in the overall outcome of the surgery. Future research into foot surgery should incorporate the complexity of how patients determine their outcome Disclosure statement: All authors have declared no conflicts of interes

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

The safety and efficacy of a policy of sedation versus no sedation in the performance of upper gastrointestinal endoscopy : a randomized controlled trial

Esophagogastroduodenal endoscopy (EGDE) is the most commonly performed endoscopic procedure in Canada and represents 51--65% of all gastrointestinal procedures performed in teaching hospitals. The routine use of conscious sedation during EGDE has facilitated its diffusion, ensured patient and physician satisfaction and has increased the potential risk of cardiorespiratory morbidity. It remains unclear if all adult ambulatory patients require routine conscious sedation prior to diagnostic EGDE, as the efficacy and safety of such a policy has not been rigorously studied in a North American population.Patients were randomly assigned to sedation or placebo in a double-blind trial.So far 360 patients of the anticipated patients have been enrolled, (182 randomized to sedation, 178 randomized to placebo). Groups were similar for all baseline characteristics. Eighty-one percent of patients randomized to placebo were able to complete EGDE without sedation. The major determinant of "successful endoscopy" was the use of sedation (OR = 7.52; 95% CI: 4.61--12.26). Preliminary subgroup analysis suggested that among patients greater than 55 yrs and with decreased pharyngeal sensitivity, there was a greater likelihood of successful unsedated endoscopy, when compared to other subsets (45% successful vs. 39% successful among the unstratified placebo population; 98% power).The use of sedation does not improve technical adequacy. However, the use of sedation in the performance of EGDE is the strongest predictor of a successful endoscopy, patient self-reported satisfaction and willingness to repeat the procedure

Osteoporosis of Crohn’s Disease: A Critical Review

Osteoporosis has long been a recognized complication of Crohn’s disease (CD), with a documented incidence ranging from 31% to 65%. The cause of osteoporosis in Crohn’s patients is likely multifactorial; corticosteroids, inflammatory cytokines, small bowel resection and the resultant calcium and vitamin D deficiencies, hypogonadism, malnutrition and the cachexia of inflammation all play a role. However, the mechanism responsible for osteoporosis associated with CD remains unclear. Treatment of decreased bone density in CD patients has been limited to calcium and vitamin D replacement. The present understanding of the pathophysiology, mechanism and treatment of osteoporosis in CD is reviewed, with the focus on the role of steroid-induced osteoporosis and the use of bisphosphonates